Hospital
Nor-Lea Hospital District
Nor-Lea Hospital District was paid $53.24M by Medicaid between Jan 2018 and Dec 2024, across 389 billing codes. Its largest line is 0202U, Oncology (prostate), multianalyte, gene expression profiling — 9.6% of everything it billed.
33Billing provider infoNOR-LEA HOSPITAL DISTRICT
LOVINGTON, NM 88260
LOVINGTON, NM 88260
33aNPI1881630036assigned 06/22/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$53.24M
24GClaims856,996
24DCodes billed389
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in New Mexico
Rank by total paid#4 of 24
Median peer was paid$20.13M
This provider vs. median2.6×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 119,325 | $6.61M | |
| 2019 | 94,824 | $6.13M | |
| 2020 | 80,372 | $4.40M | |
| 2021 | 115,173 | $6.91M | |
| 2022 | 131,975 | $7.99M | |
| 2023 | 160,994 | $10.44M | |
| 2024incomplete | 154,333 | $10.75M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | 9.6% | 13,877 | 13,281 | $5.10M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 8.1% | 31,475 | 27,984 | $4.34M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 7.8% | 15,422 | 13,968 | $4.18M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 5.8% | 7,362 | 6,531 | $3.06M |
| J0585 | Injection, onabotulinumtoxina, 1 unit | 5.1% | 3,157 | 1,754 | $2.70M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.1% | 3,227 | 2,925 | $1.65M |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 2.9% | 15,230 | 4,015 | $1.54M |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 2.8% | 3,028 | 2,930 | $1.49M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 2.4% | 26,265 | 21,232 | $1.28M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 2.2% | 15,990 | 4,846 | $1.18M |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 2.1% | 21,080 | 19,979 | $1.10M |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 2.0% | 3,104 | 2,459 | $1.09M |
377 more codes
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 1.9% | 14,883 | $1.00M |
| 99213 | Doctor's office visit, returning patient (routine) | 1.9% | 25,168 | $991K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.7% | 3,039 | $879K |
| 80053 | Comprehensive metabolic panel | 1.6% | 48,451 | $874K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.5% | 2,978 | $816K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.3% | 9,238 | $704K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.2% | 5,133 | $650K |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | 1.1% | 425 | $605K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 1.1% | 2,580 | $560K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 6,827 | $528K |
| 90837 | Psychotherapy session, about an hour | <1% | 4,768 | $511K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 51,762 | $502K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 10,226 | $475K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 7,305 | $461K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 944 | $430K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 6,133 | $429K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 1,058 | $396K |
| 71045 | Radiologic examination, chest; single view | <1% | 7,135 | $393K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 4,496 | $377K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 6,752 | $373K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 19,738 | $341K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 5,819 | $310K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 7,845 | $304K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 2,630 | $282K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 1,806 | $281K |
| 73562 | <1% | 2,723 | $270K | |
| G0378 | Hospital observation service, per hour | <1% | 1,215 | $268K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 10,469 | $268K |
| 72100 | <1% | 2,263 | $216K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 513 | $212K |
| 20610 | <1% | 1,601 | $212K | |
| 73030 | <1% | 2,340 | $211K | |
| 73630 | <1% | 2,605 | $201K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 3,573 | $197K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,703 | $192K |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 2,394 | $187K |
| 80061 | Lipid panel | <1% | 12,809 | $186K |
| 36415 | Collection of venous blood by venipuncture | <1% | 43,215 | $173K |
| 84484 | <1% | 10,164 | $170K | |
| 64615 | <1% | 1,638 | $160K | |
| 84439 | <1% | 13,485 | $159K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 1,212 | $155K |
| 73610 | <1% | 1,333 | $153K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 3,022 | $146K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 2,241 | $145K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 2,659 | $145K |
| 96376 | <1% | 2,496 | $136K | |
| 99205 | Prolong outpt/office vis | <1% | 1,623 | $136K |
| 20553 | <1% | 927 | $136K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 198 | $134K |
| 95811 | <1% | 191 | $131K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 1,730 | $126K |
| 96367 | <1% | 1,588 | $126K | |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 185 | $125K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 2,603 | $121K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 964 | $116K |
| 80074 | <1% | 1,883 | $114K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 262 | $114K |
| 74018 | <1% | 1,666 | $112K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 10,590 | $109K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 262 | $102K |
| 73130 | <1% | 1,258 | $100K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 2,409 | $98K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 3,380 | $98K |
| 81001 | <1% | 15,555 | $98K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 2,132 | $96K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 5,019 | $95K |
| 93226 | <1% | 661 | $89K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 709 | $88K |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 195 | $84K |
| 83880 | <1% | 2,778 | $82K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 7,445 | $81K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 615 | $75K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,850 | $75K |
| 73502 | <1% | 1,127 | $75K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,852 | $74K |
| 93225 | <1% | 674 | $74K | |
| 83013 | <1% | 1,108 | $74K | |
| 74178 | <1% | 133 | $71K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 762 | $70K |
| 73110 | <1% | 769 | $64K | |
| 83690 | <1% | 5,623 | $64K | |
| 86140 | <1% | 8,773 | $64K | |
| 87040 | <1% | 3,449 | $61K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 697 | $58K |
| 72040 | <1% | 596 | $56K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 529 | $56K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 2,394 | $53K |
| 83735 | <1% | 6,047 | $53K | |
| 93017 | <1% | 204 | $52K | |
| 85379 | <1% | 3,333 | $52K | |
| 83605 | <1% | 3,302 | $52K | |
| 97162 | <1% | 627 | $50K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 3,516 | $50K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 123 | $50K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 1,195 | $49K |
| 36591 | <1% | 1,096 | $48K | |
| 82728 | <1% | 3,378 | $47K | |
| 87186 | <1% | 4,107 | $47K | |
| 74022 | <1% | 428 | $46K | |
| 85652 | <1% | 10,483 | $45K | |
| 92508 | Group treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 690 | $45K |
| 86803 | <1% | 2,217 | $44K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 536 | $43K |
| 82607 | <1% | 2,856 | $42K | |
| 84481 | <1% | 2,453 | $41K | |
| 85027 | <1% | 4,560 | $36K | |
| 71250 | <1% | 188 | $36K | |
| 87077 | <1% | 3,986 | $36K | |
| 00170 | Anesthesia for intraoral procedures, including biopsy | <1% | 237 | $35K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 2,162 | $35K |
| 83540 | <1% | 4,180 | $33K | |
| 83550 | <1% | 3,539 | $33K | |
| 82570 | <1% | 4,574 | $32K | |
| 72110 | <1% | 276 | $32K | |
| 87493 | <1% | 874 | $32K | |
| 96415 | <1% | 310 | $31K | |
| 82150 | <1% | 3,051 | $31K | |
| 73560 | <1% | 405 | $30K | |
| 00731 | <1% | 255 | $30K | |
| 76830 | Ultrasound, transvaginal | <1% | 234 | $30K |
| 84702 | <1% | 1,244 | $29K | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 2,246 | $28K |
| 97161 | <1% | 498 | $28K | |
| 74019 | <1% | 212 | $28K | |
| 64483 | <1% | 50 | $28K | |
| 92567 | <1% | 963 | $28K | |
| 82043 | <1% | 3,289 | $28K | |
| 87480 | <1% | 1,312 | $27K | |
| J1439 | Injection, ferric carboxymaltose, 1 mg | <1% | 20 | $27K |
| 86038 | <1% | 1,845 | $27K | |
| 87510 | <1% | 1,312 | $27K | |
| 87660 | <1% | 1,313 | $27K | |
| 73564 | <1% | 251 | $27K | |
| 80076 | <1% | 2,457 | $26K | |
| 76536 | <1% | 211 | $26K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 1,252 | $25K |
| 87902 | <1% | 72 | $25K | |
| 00813 | <1% | 195 | $25K | |
| 81025 | <1% | 2,038 | $24K | |
| 80306 | <1% | 993 | $24K | |
| 85610 | <1% | 4,268 | $24K | |
| 76770 | <1% | 184 | $24K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 445 | $22K |
| 84703 | <1% | 1,438 | $21K | |
| 11043 | <1% | 216 | $20K | |
| 76642 | <1% | 135 | $20K | |
| 90832 | Psychotherapy session, about 30 minutes | <1% | 260 | $20K |
| 97016 | <1% | 928 | $20K | |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 3,444 | $20K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 43 | $17K |
| 82803 | <1% | 612 | $17K | |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | <1% | 13 | $17K |
| 36600 | <1% | 634 | $17K | |
| 94760 | <1% | 831 | $17K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 95 | $16K |
| 80305 | <1% | 1,501 | $15K | |
| 84145 | <1% | 581 | $15K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 8,537 | $15K |
| 99309 | Subsequent nursing facility care, per day, low to moderate complexity | <1% | 561 | $15K |
| 86480 | <1% | 291 | $15K | |
| 87522 | Neg quan hep c or qual rna | <1% | 219 | $14K |
| 86200 | <1% | 951 | $14K | |
| 87070 | <1% | 1,131 | $14K | |
| 83970 | <1% | 417 | $14K | |
| 85730 | <1% | 1,489 | $14K | |
| 90833 | Psychotherapy, 30 minutes with patient when performed with an E&M service (add-on) | <1% | 268 | $13K |
| 86703 | <1% | 600 | $12K | |
| 99220 | <1% | 173 | $12K | |
| 86431 | <1% | 1,835 | $12K | |
| 0352U | <1% | 424 | $12K | |
| 88142 | <1% | 585 | $12K | |
| 84153 | <1% | 684 | $12K | |
| J0248 | Injection, remdesivir, 1 mg | <1% | 25 | $12K |
| 82550 | <1% | 1,364 | $12K | |
| J3490 | Unclassified drugs | <1% | 566 | $12K |
| 82565 | <1% | 2,300 | $12K | |
| 84550 | <1% | 2,180 | $12K | |
| M0245 | Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring | <1% | 21 | $11K |
| 90847 | Family psychotherapy with the patient present, 50 minutes | <1% | 111 | $11K |
| 86780 | <1% | 776 | $11K | |
| 87507 | <1% | 685 | $11K | |
| 76981 | <1% | 86 | $10K | |
| 99223 | Prolong inpt eval add15 m | <1% | 97 | $10K |
| 83001 | <1% | 500 | $10K | |
| 82962 | <1% | 2,356 | $10K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 6,858 | $10K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 5,665 | $10K |
| 97165 | <1% | 156 | $10K | |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 50 | $9K |
| 83655 | <1% | 602 | $9K | |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 23 | $9K |
| 93227 | <1% | 434 | $9K | |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 1,659 | $9K |
| 72072 | <1% | 81 | $9K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 2,497 | $9K |
| 97116 | <1% | 219 | $8K | |
| 86706 | <1% | 522 | $8K | |
| 64493 | <1% | 16 | $8K | |
| 82746 | <1% | 562 | $8K | |
| J2704 | Injection, propofol, 10 mg | <1% | 3,464 | $8K |
| 00812 | <1% | 77 | $8K | |
| 84402 | <1% | 303 | $8K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 5,364 | $8K |
| 84156 | <1% | 1,164 | $8K | |
| 99239 | Hospital discharge day management, more than 30 minutes | <1% | 72 | $7K |
| 82805 | <1% | 151 | $7K | |
| 83014 | <1% | 593 | $7K | |
| 0353U | <1% | 743 | $7K | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 209 | $7K |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 2,777 | $7K |
| 90791 | Psychiatric diagnostic evaluation | <1% | 41 | $7K |
| 73140 | <1% | 78 | $7K | |
| 93880 | <1% | 50 | $7K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 3,958 | $7K |
| 92553 | <1% | 54 | $6K | |
| 82947 | <1% | 1,501 | $6K | |
| 86696 | <1% | 334 | $6K | |
| 99233 | Hospital visit by a doctor, follow-up day (complex) | <1% | 56 | $6K |
| 84270 | <1% | 309 | $6K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 175 | $6K |
| 77066 | Tomosynthesis, mammo | <1% | 32 | $6K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 3,441 | $6K |
| 86376 | <1% | 358 | $6K | |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | <1% | 62 | $6K |
| 00811 | <1% | 67 | $6K | |
| 82670 | <1% | 180 | $5K | |
| 86704 | <1% | 296 | $5K | |
| 97163 | <1% | 53 | $5K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 18 | $5K |
| 81003 | <1% | 1,271 | $5K | |
| 92523 | <1% | 24 | $5K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 2,142 | $5K |
| 85007 | <1% | 963 | $5K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 50 | $5K |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | <1% | 68 | $5K |
| 80377 | <1% | 202 | $5K | |
| 87338 | <1% | 291 | $5K | |
| 20611 | <1% | 18 | $5K | |
| 86708 | <1% | 256 | $4K | |
| 86850 | <1% | 366 | $4K | |
| 87340 | <1% | 325 | $4K | |
| H0049 | Alcohol and/or drug screening | <1% | 80 | $4K |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 494 | $4K |
| 86695 | <1% | 292 | $4K | |
| A9270 | Non-covered item or service | <1% | 1,847 | $4K |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | <1% | 209 | $4K |
| 87430 | <1% | 254 | $4K | |
| 83615 | <1% | 540 | $4K | |
| 87254 | <1% | 160 | $4K | |
| 83002 | <1% | 168 | $4K | |
| 97113 | <1% | 31 | $3K | |
| 77080 | <1% | 44 | $3K | |
| 82140 | <1% | 234 | $3K | |
| 95806 | <1% | 13 | $3K | |
| 86900 | <1% | 467 | $3K | |
| 87205 | <1% | 518 | $3K | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 115 | $3K |
| 90756 | <1% | 88 | $3K | |
| 90792 | Psychiatric diagnostic evaluation with medical services | <1% | 24 | $3K |
| 86160 | <1% | 189 | $3K | |
| 86901 | <1% | 468 | $3K | |
| 36430 | <1% | 13 | $3K | |
| 73590 | <1% | 30 | $3K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 2,076 | $3K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 907 | $3K |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 111 | $3K |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 226 | $3K |
| 11721 | <1% | 48 | $3K | |
| 80069 | <1% | 255 | $3K | |
| 72114 | <1% | 21 | $2K | |
| 94010 | <1% | 14 | $2K | |
| 86592 | <1% | 336 | $2K | |
| 82105 | <1% | 130 | $2K | |
| 82553 | <1% | 167 | $2K | |
| 90836 | <1% | 33 | $2K | |
| 92551 | <1% | 138 | $2K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 75 | $2K |
| 73090 | <1% | 31 | $2K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 199 | $2K |
| 95886 | <1% | 38 | $2K | |
| 85018 | <1% | 532 | $2K | |
| 76641 | <1% | 16 | $2K | |
| 93971 | <1% | 16 | $2K | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 1,660 | $2K |
| 97602 | <1% | 20 | $2K | |
| 84403 | <1% | 54 | $2K | |
| 97597 | <1% | 23 | $2K | |
| 82274 | <1% | 109 | $2K | |
| 83525 | <1% | 104 | $2K | |
| 82390 | <1% | 130 | $2K | |
| 73080 | <1% | 13 | $2K | |
| 81002 | <1% | 633 | $1K | |
| 97150 | Therapeutic procedure(s), group (2 or more individuals) | <1% | 53 | $1K |
| 97802 | <1% | 14 | $1K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 314 | $1K |
| 84146 | <1% | 63 | $1K | |
| J0136 | Injection, acetaminophen (b braun), not therapeutically equivalent to j0131, 10 mg | <1% | 408 | $1K |
| Q9965 | Low osmolar contrast material, 100-199 mg/ml iodine concentration, per ml | <1% | 380 | $1K |
| 95909 | <1% | 12 | $1K | |
| 82248 | <1% | 218 | $1K | |
| 92552 | <1% | 42 | $1K | |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 473 | $1K |
| 86255 | <1% | 64 | $1K | |
| 80329 | <1% | 118 | $1K | |
| 80320 | <1% | 146 | $1K | |
| 86920 | <1% | 21 | $1K | |
| 84100 | <1% | 223 | $1K | |
| 69210 | <1% | 26 | $979.14 | |
| 97803 | <1% | 13 | $930.02 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 688 | $928.15 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 701 | $868.07 |
| 90853 | Group psychotherapy (other than of a multiple-family group) | <1% | 29 | $837.52 |
| 86812 | <1% | 40 | $827.66 | |
| 85014 | <1% | 162 | $815.03 | |
| 95908 | <1% | 13 | $799.77 | |
| 82310 | <1% | 162 | $797.29 | |
| 84425 | <1% | 41 | $781.30 | |
| 97166 | <1% | 13 | $765.20 | |
| 86381 | <1% | 28 | $755.30 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 367 | $695.90 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,076 | $683.56 |
| 99232 | Hospital visit by a doctor, follow-up day | <1% | 38 | $659.12 |
| 86015 | <1% | 43 | $627.76 | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 87 | $627.29 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 101 | $593.18 |
| 83520 | <1% | 27 | $590.64 | |
| J1815 | Injection, insulin, per 5 units | <1% | 657 | $563.50 |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 12 | $537.20 |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | <1% | 17 | $491.60 |
| J1010 | Injection, methylprednisolone acetate, 1 mg | <1% | 186 | $425.10 |
| 82977 | <1% | 47 | $424.92 | |
| 82077 | <1% | 16 | $420.95 | |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 93 | $420.00 |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 29 | $416.89 |
| 90839 | <1% | 17 | $412.45 | |
| 99217 | <1% | 28 | $359.03 | |
| 84165 | <1% | 28 | $350.05 | |
| 90658 | <1% | 29 | $346.76 | |
| 80143 | <1% | 13 | $339.00 | |
| 90715 | <1% | 13 | $325.92 | |
| G2012 | Brief communication technology-based service, e.g. virtual check-in, by a physician or other qualified health care professional who can report evaluation and management services, provided to an established patient, not originating from a related e/m service provided within the previous 7 days nor leading to an e/m service or procedure within the next 24 hours or soonest available appointment; 5-10 minutes of medical discussion | <1% | 90 | $319.29 |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 63 | $313.03 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 438 | $294.37 |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 168 | $286.43 |
| 86308 | <1% | 30 | $279.89 | |
| 82040 | <1% | 52 | $264.92 | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 24 | $256.66 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 52 | $247.40 |
| 80349 | <1% | 27 | $239.58 | |
| G2211 | Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) | <1% | 16 | $224.00 |
| 86334 | <1% | 14 | $222.09 | |
| 80324 | <1% | 36 | $218.28 | |
| 84590 | <1% | 13 | $189.34 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 237 | $185.36 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 247 | $180.72 |
| 83516 | <1% | 13 | $171.71 | |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 27 | $165.57 |
| 84630 | <1% | 13 | $145.39 | |
| 84478 | <1% | 15 | $139.18 | |
| 84144 | <1% | 12 | $137.48 | |
| 80361 | <1% | 14 | $112.69 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 98 | $109.34 |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | <1% | 687 | $100.81 |
| 84520 | <1% | 13 | $77.31 | |
| V2632 | Posterior chamber intraocular lens | <1% | 14 | $75.60 |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 21 | $50.90 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 15 | $32.87 |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 15 | $31.47 |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 14 | $29.21 |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 17 | $28.80 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | <1% | 16 | $25.41 |
| J1580 | Injection, garamycin, gentamicin, up to 80 mg | <1% | 32 | $19.47 |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 15 | $17.50 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 17 | $12.25 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 28 | $0.44 |
| 80050 | General health panel | 0% | 63 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSHAW, DAVID (CEO ADMINISTRATOR)
Parent organizationNOR-LEA HOSPITAL DISTRICT
| Provider | Location | Paid |
|---|---|---|
| Nor-Lea Hospital District | Lovington, NM | $18.25M |
| Nor-Lea Hospital District | Hobbs, NM | $6.83M |
| Nor-Lea Hospital District | Hobbs, NM | $2.02M |
| Nor-Lea Hospital District | Tatum, NM | $254K |
| Nor-Lea Hospital District | Lovington, NM | $251K |
| Nor-Lea Hospital District | Lovington, NM | $98K |
| Nor-Lea Hospital District | Hobbs, NM | $12K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.